PHARMACEUTICAL 2024

China Pharma Holdings INC
Rank 144 of 309



RealRate

PHARMACEUTICAL 2024

China Pharma Holdings INC
Rank 144 of 309

China Pharma Holdings, Inc.

The relative strengths and weaknesses of China Pharma Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of China Pharma Holdings INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 92% points.The greatest weakness of China Pharma Holdings INC is the variable Assets, Current, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 232%, being 19% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	5,997
Cost of Goods Sold	7,292
Intangible Assets	3,255
Liabilities, Current	6,821
Liabilities, Non-Current	40
Other Assets	117
Other Compr. Net Income	-121
Other Expenses	765
Other Liabilities	2,154
Other Net Income	-327
Other Revenues	7,011
Property and Equipment	7,100
Research and Development	240
Selling, General and Administrative Expense	1,466

Output Variable	Value in 1000 USD
Assets	16,469
Liabilities	9,015
Expenses	9,763
Revenues	7,011
Stockholders Equity	7,455
Net Income	-3,079
Comprehensive Net Income	-3,139
BaseVar	21,353
ECR before LimitedLiability	103%
Economic Capital Ratio	232%